Kinamycins A and C, bacterial metabolites that contain an unusual diazo group, as potential new anticancer agents: Antiproliferative and cell cycle effects

Anti-Cancer Drugs

Volumn 17, Issue 7, 2006, Pages 825-837

  Hasinoff, Brian B ^a   Wu, Xing ^a   Yalowich, Jack C ^c   Goodfellow, Valerie ^b   Laufer, Radoslaw S ^b   Adedayo, Otunola ^b   Dmitrienko, Gary I ^b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF WATERLOO   (Canada)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Anticancer drug; Apoptosis; Cell cycle; Cell cycle block; Cytotoxicity; Kinamycin; Topoisomerase I; Topoisomerase II

Indexed keywords

ANTINEOPLASTIC AGENT; DIAZONIUM COMPOUND; DITHIOTHREITOL; DNA; DNA TOPOISOMERASE (ATP HYDROLYSING); KINAMYCIN; QUINONE DERIVATIVE; THIOL DERIVATIVE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CATALYSIS; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL LINE; CELL PROLIFERATION; CLUSTER ANALYSIS; CONTROLLED STUDY; DNA CROSS LINKING; DRUG ACTIVITY; DRUG EFFECT; DRUG RESPONSE; DRUG STRUCTURE; HUMAN; INCUBATION TIME; INTERCALATION COMPLEX; NONHUMAN; PRIORITY JOURNAL;

ADENOSINE TRIPHOSPHATASES; ADENOSINE TRIPHOSPHATE; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIGENS, NEOPLASM; AZO COMPOUNDS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CHO CELLS; CLUSTER ANALYSIS; CRICETINAE; CROSS-LINKING REAGENTS; DNA GYRASE; DNA TOPOISOMERASES, TYPE II; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA, NEOPLASM; DNA, SUPERHELICAL; DNA-BINDING PROTEINS; ESCHERICHIA COLI; HUMANS; K562 CELLS; NAD; NAPHTHOQUINONES; PLASMIDS; QUINONES; TOPOISOMERASE II INHIBITORS;

EID: 33748157438     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cad.0000224442.78211.27     Document Type: Article

References (41)

1. Omura S, Nakagawa A, Yamada H, Hata T, Furusaki A, Watanabe T. Structure of kinamycin C, and the structural relation among kinamycin A, B, C, and D. Chem Pharm Bull 1971; 19:2428-2430.
2. Omura S, Nakagawa A, Yamada H, Hata T, Furukawa A, Watanabe T. Structures and biological properties of kinamycin A, B, C, and D. Chem Pharm Bull 1973; 21:931-940.
3. Moore HW. Bioactivation as a model for drug design bioreductive alkylation. Science 1977; 197:527-532.
4. Mithani S, Weeratunga G, Taylor J, Dmitienko GI. The kinamycins are diazofluorenes and not cyanocarbazoles. J Am Chem Soc 1994; 116:2209-2210.
5. Gould SJ, Tamayo N, Melville CR, Cone MC. Revised structures for the kinamycin antibiotics: 5-diazobenzo[b]fluorenes rather than benzo[b]carbazole cyanamides. J Am Chem Soc 1994; 116:2207-2208.
6. Feldman KS, Eastman KJ. A proposal for the mechanism-of-action of diazoparaquinone natural products. J Am Chem Soc 2005; 127:15344-15345.
7. He H, Ding WD, Bernan VS, Richardson AD, Ireland CM, Greenstein M, et al. Lomaiviticins A and B, potent antitumor antibiotics from Micromonospora lomaivitiensis. J Am Chem Soc 2001; 123:5362-5363.
8. Laufer RS, Dmitrienko GI. Diazo group electrophilicity in kinamycins and lomaiviticin A: potential insights into the molecular mechanism of antibacterial and antitumor activity. J Am Chem Soc 2002; 124:1854-1855.
9. Cone MC, Seaton PJ, Halley KA, Gould SJ. New products related to kinamycin from Streptomyces murayamaensis. I. Taxonomy, production, isolation and biological properties. J Antibiot (Tokyo) 1989; 42:179-188.
10. 2(levrazoxane), of the topoisomerase II inhibitors dexrazoxane (ICRF-187) and levrazoxane (ICRF-186). J Inorg Biochem 2004; 98:616-624.
11. Hasinoff BB, Kuschak TI, Creighton AM, Fattman CL, Allan WP, Thampatty P, et al. Characterization of a Chinese hamster ovary cell line with acquired resistance to the bisdioxopiperazine dexrazoxane (ICRF-187) catalytic inhibitor of topoisomerase II. Biochem Pharmacol 1997; 53:1843-1853.
12. Hasinoff BB, Kozlowska H, Creighton AM, Allan WP, Thampatty P, Yalowich JC. Mitindomide is a catalytic inhibitor of DNA topoisomerase II that acts at the bisdioxopiperazine binding site. Mol Pharmacol 1997; 52:839-845.
13. Ritke MK, Yalowich JC. Altered gene expression in human leukemia K562 cells selected for resistance to etoposide. Biochem Pharmacol 1993; 46:2007-2020.
14. Ritke MK, Allan WP, Fattman C, Gunduz NN, Yalowich JC. Reduced phosphorylation of topoisomerase II in etoposide-resistant human leukemia K562 cells. Mol Pharmacol 1994; 46:58-66.
15. Ritke MK, Roberts D, Allan WP, Raymond J, Bergoltz VV, Yalowich JC. Altered stability of etoposide-induced topoisomerase II-DNA complexes in resistant human leukemia K562 cells. Br J Cancer 1994; 69:687-697.
16. Fattman C, Allan WP, Hasinoff BB, Yalowich JC. Collateral sensitivity to the bisdioxopiperazine dexrazoxane (ICRF-187) in etoposide (VP-16) resistant human leukemia K562 cells. Biochem Pharmacol 1996; 52:635-642.
17. Hasinoff BB, Abram ME, Barnabé N, Khelifa T, Allan WP, Yalowich JC. The catalytic DNA topoisomerase II inhibitor dexrazoxane (ICRF-187) induces differentiation and apoptosis in human leukemia K562 cells. Mol Pharmacol 2001; 59:453-461.
18. Barnabé N, Hasinoff BB. High-throughput fluorescence flow injection topoisomerase II inhibition assay. J Chromatogr B Biomed Sci Appl 2001; 760:263-269.
19. Hasinoff BB, Wu X, Krokhin OV, Ens W, Standing KG, Nitiss JL, et al. Biochemical and proteomics approaches to characterize topoisomerase IIα cysteines and DNA as targets responsible for cisplatin-induced inhibition of topoisomerase IIα. Mol Pharmacol 2005; 67:937-947.
20. Lindsley JE, Wang JC. On the coupling between ATP usage and DNA transport by yeast DNA topoisomerase II. J Biol Chem 1993; 268:8096-9104.
21. Burden DA, Froelich-Ammon SJ, Osheroff N. Topoisomerase II-mediated cleavage of plasmid DNA. Methods Mol Biol 2001; 95:283-289.
22. Rabow AA, Shoemaker RH, Sausville EA, Covell DG. Mining the National Cancer Institute's tumor-screening database: identification of compounds with similar cellular activities. J Med Chem 2002; 45:818-840.
23. Kang YJ, Zhou ZX, Wang GW, Buridi A, Klein JB. Suppression by metallothionein of doxorubicin-induced cardiomyocyte apoptosis through inhibition of p38 mitogen-activated protein kinases. J Biol Chem 2000; 275:13690-13698.
24. Fortune JM, Osheroff N. Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice. Prog Nucleic Acid Res Mol Biol 2000; 64:221-253.
25. Li TK, Liu LF. Tumor cell death induced by topoisomerase-targeting drugs. Annu Rev Pharmacol Toxicol 2001; 41:53-77.
26. Yalowich JC, Thampatty P, Allan WP, Chee G-L, Hasinoff BB. Acquired resistance to ICRF-187 (dexrazoxane) in a CHO cell line is associated with a point mutation in DNA topoisomerase IIα (topo II) and decreased drug-induced DNA-enzyme complexes. Proc Am Assoc Cancer Res 1998; 39:375.
27. Classen S, Olland S, Berger JM. Structure of the topoisomerase II ATPase region and its mechanism of inhibition by the chemotherapeutic agent ICRF-187. Proc Natl Acad Sci U S A 2003; 100:10629-10634.
28. Classen S, Olland S, Berger JM. Structure of the topoisomerase II ATPase region and its mechanism of inhibition by the chemotherapeutic agent ICRF-187. Proc Natl Acad Sci U S A 2003; 100:14510.
29. Sinha BK. Topoisomerase inhibitors. A review of their therapeutic potential in cancer. Drugs 1995; 49:11-19.
30. Friedberg EC. DNA damage and repair. Nature 2003; 421:436-440.
31. Pilch DR, Sedelnikova OA, Redon C, Celeste A, Nussenzweig A, Bonner WM. Characteristics of γ-H2AX foci at DNA double-strand breaks sites. Biochem Cell Biol 2003; 81:123-129.
32. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 1998; 273:5858-5868.
33. Ritke MK, Rusnak JM, Lazo JS, Allan WP, Dive C, Heer S, et al. Differential induction of etoposide-mediated apoptosis in human leukemia HL-60 and K562 cells. Mol Pharmacol 1994; 46:605-611.
34. McGahon A, Bissonnette R, Schmitt M, Cotter KM, Green DR, Cotter TG. BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood 1994; 83:1179-1187.
35. Hasinoff BB, Yalowich JC, Ling Y, Buss JL. The effect of dexrazoxane (ICRF-187) on doxorubicin- and daunorubicin-mediated growth inhibition of Chinese hamster ovary cells. Anticancer Drugs 1996; 7:558-567.
36. Hasinoff BB, Wu X, Begleiter A, Guziec L, Guziec F, Giorgianni A, et al. Structure-activity study of the interaction of bioreductive benzoquinone alkylating agents with DNA topoisomerase II. Cancer Chemother Pharmacol 2006; 57:221-233.
37. Jensen LH, Renodon-Corniere A, Wessel I, Langer SW, Sokilde B, Carstensen EV, et al. Maleimide is a potent inhibitor of topoisomerase II in vitro and in vivo: a new mode of catalytic inhibition. Mol Pharmacol 2002; 61:1235-1243.
38. Gantchev TG, Hunting DJ. The ortho-quinone metabolite of the anticancer drug etoposide (VP-16) is a potent inhibitor of the topoisomerase II/DNA cleavable complex. Mol Pharmacol 1998; 53:422-428.
39. Wang H, Mao Y, Chen AY, Zhou N, LaVoie EJ, Liu LF. Stimulation of topoisomerase II-mediated DNA damage via a mechanism involving protein thiolation. Biochemistry 2001; 40:3316-3323.
40. Lindsey RH Jr, Bromberg KD, Felix CA, Osheroff N. 1,4-Benzoquinone is a topoisomerase II poison. Biochemistry 2004; 43:7563-7574.
41. Paz MM, Tomasz M. Reductive activation of mitomycin A by thiols. Org Lett 2001; 3:2789-2792.